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The study of human genetic variation represents a major chapter in the history of modern 
medicine and still holds the fascinating promise of identifying the genetic architecture of a 
large number of disease traits [1, 2]. This is particularly relevant nowadays, in light of the 
prospective rising trends in the global incidence and prevalence of type 2 diabetes [3]. 
However, the non-communicable diseases, such as type 2 diabetes, carry a considerable 
burden of complexity, as a result of the combination of genetic, epigenetic and environmental 
risk factors [4], which complicate the understanding of type 2 diabetes genetic background 
and its potential clinical transferability in terms of prognostic and preventive rules or 
potentially novel drug targets. 
The technical and methodological advancements, as well as the knowledge accrued over the 
past decade on the haplotype block structure of the human genome [1, 5], have enabled 
investigators to tackle the complexity of the genetic architecture of type 2 diabetes in 
populations of European and non-European descent by performing large-scale genome-wide 
association studies (GWAS) for both common and rare genetic variants [2, 6]. To date, the 
international research consortia leading these initiatives have identified over 90 genetic loci 
credibly associated with a higher risk of type 2 diabetes, and more are expected in the years 
to come. When considered in aggregate, the loci identified explain only a limited proportion 
of the type 2 diabetes liability-scale variance, possibly because the actual number of the 
entire spectrum of type 2 diabetes risk loci has yet to be identified, or because the causal 
variant(s) harbored in or near these loci, as well as the underlying biological pathways, 
remain to be elucidated in most instances. 
Interestingly, while interpreting the GWAS results one may observe that as the number of 
identified type 2 diabetes risk variants has increased over time, and the loci uncovered by 
earlier GWAS have been further replicated in larger association studies, the individual (per-
allele) effect estimate has become smaller than the one originally detected in the discovery 
GWAS [7]. In addition, since novel variants are generally lower in frequency, ever larger 
sample sizes are needed to detect these effects in both the discovery and replication cohorts. 
The primary estimate of an inappropriately large effect size in case of newly identified 
variants is a known statistical phenomenon, usually dubbed as ‘winner´s curse’, whereby the 
multiple repetition of the association test in cohorts of adequate sample size leads to further 
refinements of the original effect size estimate, generally towards lower absolute values [2]. 
Another explanation for the possible inflation in the initial estimate of the single variant 
attributable risk stems from the case–control study design of the discovery GWAS, which is 
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inherently characterised by a disproportionate abundance of cases over controls compared 
with the real-world setting of population-based studies [2]. This phenomenon is also known 
as the ‘spectrum bias’ effect, and may be overcome by re-estimating the actual effect sizes of 
known type 2 diabetes risk variants in real-world populations.  
Notably, as most of the type 2 diabetes risk loci have been identified in individuals of 
European ancestry, the population attributable risk for these variants in other ethnicities may 
be different, depending on the haplotype block structure (i.e. the linkage-disequilibrium map) 
of the population ancestry considered. A recently published trans-ethnic meta-analysis 
revealed that a considerable proportion of the variants originally identified in Europeans are 
shared across populations of diverse ethnicity and show directionally consistent effects [8], 
highlighting the opportunity to extrapolate insights on type 2 diabetes genetic susceptibility 
in Europeans to non-European populations. These observations are particularly relevant in 
that the unbiased estimate of the effect size and the strength of the statistical association with 
type 2 diabetes risk are both used to prioritise the inclusion of loci in reliable type 2 diabetes 
risk prediction models and, eventually, in fine-mapping and functional characterisation 
studies.  
 
In this issue of Diabetologia, investigators working on behalf of the China Kadoorie Biobank 
(CKB) Collaborative Group provide a demonstration of the calculation of (relatively) 
unbiased allelic effect sizes for a set of 56 established type 2 diabetes risk variants in a large 
population-based cohort study of Chinese adult individuals, including ∼7,100 type 2 diabetes 
cases and ∼86,000 non-diabetic controls [9]. These variants were tested for association with 
type 2 diabetes risk in the CKB cohort, and the results were then combined in a meta-analysis 
with those from the Asian Genetic Epidemiology Network Type 2 Diabetes (AGEN-T2D) 
Consortium, thus bringing the sample size up to ∼32,100 cases and ∼115,600 controls. The 
resulting effect estimates for the vast majority of the variants were highly concordant and 
directionally consistent with the original reports from existing meta-analyses of GWAS 
conducted in Europeans and East Asians. However, the authors observed a consistent 
proportional reduction (∼20%) in the log OR of the allelic effect sizes estimated in CKB 
compared with those reported in AGEN-T2D and in GWAS of European case–control 
samples.  
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The authors suggest the occurrence of the ‘spectrum bias/winner’s curse’ effects as possible 
explanations for this phenomenon [9]. Although this might be reasonably the case, the lower 
individual effect size detected in Chinese individuals might rather reflect the different 
haplotype patterns between European and Asian ancestries. However, this might not be a 
tenable assumption in this specific instance, as the trend towards decreased effect sizes was 
evident in the comparison of CKB vs AGEN-T2D as well as that of CKB vs Europeans. The 
linkage-disequilibrium patterns might instead account for the heterogeneity of effect 
occurring in isolated cases, such as the RBMS1 rs7593730 and GCC1–PAX4 rs6467136 loci, 
which appeared to be associated with type 2 diabetes risk only in Europeans and East Asians, 
respectively. However, as also pointed by the authors, a comprehensive explanation of the 
ethnic differences is currently elusive in the absence of fine-mapping studies at these loci. Of 
note, the individuals in the CKB cohort included a considerable proportion (~19%) of first-
degree relatives. However, the authors conducted thorough sensitivity analyses, and the 
exclusion of those individuals did not appreciably impact the estimates of the effect sizes.  
In addition, the authors successfully tested the performance of a weighted genetic risk score 
comprising the whole set of 52 type 2 diabetes susceptibility variants (GRS-T) on type 2 
diabetes predictability in the CKB cohort. The same analyses were extended to sub-GRSs 
comprised of a limited set of loci with prior evidence of effect on beta cell function (GRS-
BC, n=25 loci) or insulin-resistance (GRS-IR, n=7 loci) [9]. Although we might share with 
the authors the confidence that the unbiased estimate of the individual allelic weights for the 
variants comprised in the scores plays in favour of the generalisability of these findings to the 
Chinese population, we should however bear in mind that the inclusion of genetic 
information does not remarkably outperform existing clinical type 2 diabetes risk prediction 
models [10]. Moreover, the sub-GRS classifications were intrinsically weakened by the lack 
of internal validation in the CKB cohort, as the relevant metrics of beta cell function and 
insulin resistance were not available. Finally, the authors identified a significant interaction 
of adiposity measures with GRS-T and GRS-BC (but not GRS-IR), with leaner individuals 
carrying a proportionally higher type 2 diabetes genetic risk burden.  
 
The current analysis of the CKB cohort is per se relevant, as it confirms the existence of a 
shared genetic background between Chinese and European populations, and provides a clear 
demonstration of extant upward biased estimates for the effect size of type 2 diabetes risk 
variants originally drawn from the discovery cohorts. As anticipated to a certain extent [2], 
The Editor’s version has been published online first on April 26th, 2016 in Diabetologia. 
The final publication is available at Springer via http://dx.doi.org/10.1007/s00125-016-3962-z 
 
 5 
these findings lessen the actual population attributable risk carried by established type 2 
diabetes risk GWAS variants in Chinese individuals, and may be of help to prioritise loci for 
further functional interrogation. 
This study is also interesting with regard to the nature of the analysis conducted. The attempt 
to replicate the associations of known loci with type 2 diabetes risk to obtain unbiased 
population-based estimates is not a discovery-driven exercise. As such, the attainment of 
genome-wide significance at all loci included in the analysis is not a conditio sine qua non to 
judge the relevance of the estimates, as it would require much larger sample sizes that are 
difficult to collect. However, if the population-based genome-wide scan were to be 
discovery-driven, the pitfall of eventually failing to reach genome-wide significance for the 
variants included in the association test would eventually lead to higher rates of false-
negative results. Hence, in these specific situations, it might not be entirely heretical to apply 
less conservative type I error rate thresholds, although the absence of a solid standard entails 
some elements of uncertainty at discriminating some results as informative against the risk of 
being overly permissive. Whether the GWAS approach should remain a matter of statistical 
constraints only, or whether its integration with functional maps [11, 12] may highlight some 
sub-threshold loci as informative as those that reach genome-wide significance, is still an 
open question, which might be worth pursuing further.  
In conclusion, the work of the CKB Collaborative Group is a remarkable example of the 
uncertainty that characterises the estimate of single variant-attributable risk and the 
dependence of its statistical relevance on the reference context. For example, every 
population cohort larger than the CKB herein discussed would provide less biased effect size 
estimates; therefore, the effect sizes estimated in the current CKB cohort, represent, by now, 
the best guess of what could be reasonably called ‘true’. However, clinicians care more about 
the translational and biological relevance of genetic discoveries. Hence, in case obtaining 
ever larger sample sizes would not be practical, thus preventing the available estimate to be 
further improved, how could the statistical relevance be informed by the context? The 
complementary information that could arise from the full integration of the genetic and 
functional maps holds the promise of potentially uncovering clinically relevant mechanistic 
insights and might expand the regulatory framework in which to interpret the functional 
follow-up and fine-mapping currently ongoing at established type 2 diabetes risk loci.  
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